Ranchi News Desk

Advanced Renal Cell Carcinoma Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

 Breaking News
  • No posts were found

Advanced Renal Cell Carcinoma Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

February 22
17:12 2023
Advanced Renal Cell Carcinoma Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight’s, “Advanced Renal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Advanced Renal Cell Carcinoma pipeline landscape. It covers the Advanced Renal Cell Carcinoma pipeline drug profiles, including Advanced Renal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Advanced Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Advanced Renal Cell Carcinoma emerging drugs, the Advanced Renal Cell Carcinoma pipeline analysis report provides a 360° view of the Advanced Renal Cell Carcinoma pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Advanced Renal Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Advanced Renal Cell Carcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Advanced Renal Cell Carcinoma clinical trials studies, Advanced Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report

 

  • Over 40+ Advanced Renal Cell Carcinoma companies are evaluating 40+ Advanced Renal Cell Carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Advanced Renal Cell Carcinoma market would significantly increase market revenue.

 

  • The leading Advanced Renal Cell Carcinoma Companies includes Roche, Nektar Therapeutic, MedImmune LLC, CoImmune, X4 Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Apexigen, Inc.,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Aravive, Inc., Arrowhead Pharmaceuticals, Merck, Apollomics, Astex Pharmaceuticals, Peloton Therapeutics, Inc., Infinity Pharmaceuticals, Surface Oncology, AO GENERIUM, CRISPR Therapeutics AG, and others.

 

  • Promising Advanced Renal Cell Carcinoma Pipeline Therapies includes ABT-869, Cabozantinib, tivozanib (AV-951), Sorafenib, Temsirolimus (CCI-779), Pazopanib + interferon alpha 2A, Nivolumab, Ipilimumab, Sunitinib, and others.

 

  • The Advanced Rena Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The Advanced Rena Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.

 

To explore more information on the latest breakthroughs in the Advanced Rena Cell Carcinoma Pipeline treatment landscape of the report, click here @ Advanced Rena Cell Carcinoma Pipeline Outlook

 

Advanced Renal Cell Carcinoma Overview

 

Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That’s when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.

 

Latest Developmental Activities in the Advanced Renal Cell Carcinoma Treatment Landscape

 

  • Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient’s own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs).

 

For further information, refer to the detailed Advanced Rena Cell Carcinoma Unmet Needs, Advanced Rena Cell Carcinoma Market Drivers, and Advanced Rena Cell Carcinoma Market Barriers, click here for Advanced Renal Cell Carcinoma Ongoing Clinical Trial Analysis

 

Advanced Rena Cell Carcinoma Emerging Drugs Profile

 

  • Atezolizumab: Roche

Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7. 1 (ie, CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced Renal Cell Carcinoma.

 

  • Bempegaldesleukin (NKTR-214): Nektar Therapeutics

Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient’s own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and NK cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these effector T cells. In clinical and preclinical studies, treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment. Bempegaldesleukin has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

 

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Roche.

 

Request a sample and discover the recent advances in Advanced Renal Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Renal Cell Carcinoma Treatment Landscape

 

Scope of the Advanced Renal Cell Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Advanced Renal Cell Carcinoma Companies- Roche, Nektar Therapeutic, MedImmune LLC, CoImmune, X4 Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Apexigen, Inc.,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Aravive, Inc., Arrowhead Pharmaceuticals, Merck, Apollomics, Astex Pharmaceuticals, Peloton Therapeutics, Inc., Infinity Pharmaceuticals, Surface Oncology, AO GENERIUM, CRISPR Therapeutics AG, and others.

 

  • Advanced Renal Cell Carcinoma Pipeline Therapies- ABT-869, Cabozantinib, tivozanib (AV-951), Sorafenib, Temsirolimus (CCI-779), Pazopanib + interferon alpha 2A, Nivolumab, Ipilimumab, Sunitinib, and others.

 

  • Advanced Renal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Molecule Type, Mechanism of Action

  

Dive deep into rich insights for drugs for Advanced Renal Cell Carcinoma Market Drivers and Advanced Renal Cell Carcinoma Market Barriers, click here @ Advanced Renal Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Atezolizumab: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Guadecitabine: Astex Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. MEDI5752: MedImmune
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Advanced Renal Cell Carcinoma Key Companies
  18. Advanced Renal Cell Carcinoma Key Products
  19. Advanced Renal Cell Carcinoma- Unmet Needs
  20. Advanced Renal Cell Carcinoma- Market Drivers and Barriers
  21. Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
  22. Advanced Renal Cell Carcinoma Analyst Views
  23. Advanced Renal Cell Carcinoma Key Companies
  24. Appendix

 

Got Queries? Find out the related information on Advanced Renal Cell Carcinoma Mergers and acquisitions, Advanced Renal Cell Carcinoma Licensing Activities @ Advanced Renal Cell Carcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services